Navigation Links
Cephalon Announces Strong Third Quarter Financial Results
Date:11/8/2007

re, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.

This press release and/or the financial results attached to this press release include "Adjusted Net Income," "Basic Adjusted Income per Common Share," "Basic Adjusted Income per Common Share Guidance," and "Diluted Adjusted Income Per Common Share," amounts that are considered "non-GAAP financial measures" under SEC rules. As required, we have provided reconciliations of these measures. Additional required information is located in the Form 8-K furnished to the SEC in connection with this press release.

CEPHALON, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2007 2006 2007 2006

REVENUES:

Sales $428,729 $470,513 $1,287,802 $1,246,825

Other revenues 9,692 11,820 34,865 32,562

438,421 482,333 1,322,667 1,279,387

COSTS AND EXPENSES:

Cost of sales 82,258 83,160 251,970 250,613

Research and development 93,527 86,439 274,078 294,899

Selling, general and

administrative 186,456 161,108 527,962 470,158

Settlement reserve 369,000 - 425,000 -

Impairment charge - - - 12,417

731,241 330,707 1,479,010 1,028,087

INCOME (LOSS) FROM OPERATIONS (292,820) 15
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014  ARCH Venture Partners, one ... in the development of seed and early-stage advanced ... fund closed with more than $400 million in ... million subscription target by more than $150 million. ... the strength and potential of our approach to ...
(Date:8/27/2014)... August 27, 2014 After the boom ... that the next beverage craze is going to be ... that formulators can use Stress Relief energy pattern which ... the making of a beverage, including minerals, herbs and ... energy, channeling that power into rapid recovery and helping ...
(Date:8/27/2014)... Budding Biomedical Scientists , This ... participated in the Scientific Enrichment and Opportunity ... of Medicine . , The rigorous ... experience in the sciences and brings them in ... students for both academic and career mentoring. , ...
(Date:8/26/2014)... An analysis by Replikins, Ltd. of Pubmed data of ... virus strains has revealed extensive conservation and sharing of ... sharing of specific Replikin gene structures has permitted the ... did for the H5N1 influenza vaccine and the Taura ... to be effective (1,2). This ...
Breaking Biology Technology:Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2
... NEW YORK and MONTREAL, Dec. 21 /PRNewswire-FirstCall/ - ICBS Ltd. ... state and municipal regulatory bodies for the sale of the ... Solutions will be moving to target regulatory agencies in the ... advantages not only on time advantage (10 Hours for test ...
... III trials of OGX-011 in first- and second-line advanced ... begin in 2010 and early 2011 -- , -- ... to target resistance to cancer treatments -- , JERUSALEM, ... - Teva Pharmaceutical Industries Ltd. ( TEVA) and OncoGenex ...
... , , THOUSAND OAKS, Calif., Dec. ... Roger M. Perlmutter, M.D., Ph. D., Amgen,s executive vice ... Fellow of the American Association for the Advancement of Science ... on behalf of the advancement of science or its applications ...
Cached Biology Technology:BioSpec Global Solutions Inc. target market TOGS 9000 to state and municipal regulatory bodies in U.S. market 2Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 2Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 3Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 4Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 5Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 6Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 7Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 8Amgen's Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines 2Amgen's Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines 3
(Date:8/27/2014)... as giant, frightening beasts. But every creature is a ... slab containing fossils of 24 very young dinosaurs and ... hatchlings overseen by a caretaker, according to a new ... P. Hedrick and Peter Dodson led the work, collaborating ... where the specimen is held. Hedrick is a doctoral ...
(Date:8/27/2014)... that a deficiency in serotonin a chemical messenger ... depression. In the journal ACS Chemical Neuroscience , ... serotonin in their brains (and thus should have been ... , Donald Kuhn and colleagues at the John ... School of Medicine note that depression poses a major ...
(Date:8/27/2014)... have shown that excessive iron is closely ... Previous studies from Chunyan Guo and co-workers ... shown that baicalin prevented iron accumulation after ... 1 expression, and increased ferroportin 1 expression ... disease rats. However, the relationship between iron ...
Breaking Biology News(10 mins):Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 2Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 3New study throws into question long-held belief about depression 2
... at the U.S. Department of Energy,s Lawrence Berkeley National ... into wispy nanoscale ropes that approach the structural complexity ... development in the push to develop self-assembling nanoscale materials ... but which are rugged enough to withstand harsh conditions ...
... Energy,s Pacific Northwest National Laboratory has been recognized for ... The award-winning partnerships are helping analyze trace amounts of ... and more easily study live cells., The Federal Laboratory ... 2011 for Excellence in Technology Transfer. The consortium is ...
... have proven that you don,t have to travel to exotic ... distinctive species of crayfish in Tennessee and Alabama that is ... genetic relative, once thought to be the only species in ... in Kentucky, can grow almost as big as a lobster. ...
Cached Biology News:A nanoscale rope, and another step toward complex nanomaterials that assemble themselves 2A nanoscale rope, and another step toward complex nanomaterials that assemble themselves 3PNNL recognized for technology transfer 2PNNL recognized for technology transfer 3Researchers discover giant crayfish species right under their noses 2Researchers discover giant crayfish species right under their noses 3Researchers discover giant crayfish species right under their noses 4
Human endothelial progenitor cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Dendritic Cells...
...
...
Biology Products: